NIH convened work groups and a conference to address research and treatment for PKU.
Sapropterin may allow liberalization of a Phe-restricted diet for those who respond.
New therapies are needed to optimize quality of life across the lifespan.
Research is needed on strategies to improve access to and compliance with treatment.
Management guidelines must be based on rigorous study design and outcome measures.